2016 ACR/ARHP Annual Meeting

November 11-16, 2016. Washington, DC.

View by Number View by Title View Sessions

View by Date

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 1562

Interaction Between Antibodies to Paraoxonase 1 and PON1 rs662 Polymorphism: New Clues to Understand HDL Dysfunction and Oxidative Stress in Rheumatoid Arthritis
Abstract Number: 1639

Interchangeability of Innovator Rituximab and Its Biosimilar: Results from International Controlled Comparative 1-Year Study in Patients with Active Rheumatoid Arthritis
Abstract Number: 1232

Interdisciplinary Osteoporosis Clinical Working Group and Fracture Liaison Service at Loma Linda University Medical Center (LLUMC): Laying the Groundwork
Abstract Number: 346

Interest of Bone Texture Assessment By Trabecular Bone Score (TBS) in Kidney Transplants Recipients
Abstract Number: 1925

Interest of Procalcitonin for the Follow-up of ANCA-Associated Vasculitis: Data from a Cohort of 99 Patients
Abstract Number: 272

Interferon Chemokine Score and Other Cytokine Measures Predict Changes in Disease Activity in Patients with Juvenile and Adult Dermatomyositis
Abstract Number: 3240

Interferon Kappa Is a Novel Type I IFN That Drives Cutaneous Inflammation in Systemic Lupus
Abstract Number: 1007

Interferon Regulatory Factor 1 Is the Key Driver of Inflammasome Activity in Systemic Lupus Erythematosus
Abstract Number: 1215

Interferon Signature Genes Are Differentially Expressed Between Microscopic Polyangiitis and Systemic Lupus Erythematosus Peripheral Blood Transcriptomes
Abstract Number: 871

Interleukin 33 Critically Regulates Angiogenesis and Inflammation in Large Vessels Vasculitis
Abstract Number: 1126

Interleukin-1 Is Not Involved in Synovial Inflammation and Cartilage Destruction in Collagenase-Induced Osteoarthritis
Abstract Number: 1120

Interleukin-1β Stabilize CXCL2 mRNA and Increase Its Expression
Abstract Number: 467

Interleukin-21-Signaling in B Cells, but Not in T Cells, Is Indispensable for Development of Collagen-Induced Arthritis in Mice
Abstract Number: 873

Interleukin-23 Stimulates Inflammatory and Proliferative Pathways in Giant Cell Arteritis
Abstract Number: 1284

International Multi-Observer Ultrasound Reliability Study of Age Related Vascularization and Ossification in Healthy Children: The Omeract Pediatric Ultrasound Task Force

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].